Erasca, Inc.
Clinical trials sponsored by Erasca, Inc., explained in plain language.
-
New pill targets advanced cancers in first human tests
Disease control OngoingThis is an early-stage study to test the safety and find the right dose of a new oral drug called ERAS-601. It will be given to about 90 adults with advanced solid tumors that have spread, both by itself and combined with other cancer therapies. The main goals are to see how much…
Phase: PHASE1 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New Two-Drug attack targets Tough-to-Treat cancer mutation
Disease control OngoingThis study is testing the safety and early effectiveness of a new drug combination (naporafenib plus trametinib) for people with advanced solid tumors that have a specific genetic change called a RAS Q61X mutation. It is for patients aged 12 and older whose cancer has grown despi…
Phase: PHASE1 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New drug duo battles Tough-to-Treat skin cancer in major trial
Disease control OngoingThis study is testing whether a new combination of two drugs, naporafenib and trametinib, works better than current standard treatments for people with advanced NRAS-mutant melanoma that has continued to grow after immunotherapy. The trial will compare how long patients live with…
Phase: PHASE3 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Mar 09, 2026 14:24 UTC